Skip to main content

Table 3 Summary of case-control analysis of haplotypes associated with paclitaxel response

From: Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Gene

Haplotype

Haplotype Frequencies

Case, Control Ratio Counts

Case, Control Frequencies

Chi Square

p Value

Odds Ratio

L95

U95

GRIK1

GT

0.073

6.3 : 9.7, 2.1 : 97.9

0.394, 0.021

28.362

1.01E-07

30.28

5.56

164.98

ROBO1

AGGT

0.043

4.1 : 7.9, 0.6 : 97.4

0.339, 0.006

28.828

7.91E-08

84.25

5.10

1391.73

SGCD

AAC

0.043

4.0 : 12.0, 0.9 : 99.1

0.251, 0.009

19.847

8.39E-06

36.70

3.45

390.22

PTPRD

TGGATCCCGT

0.095

8.3 : 7.7, 2.7 : 97.3

0.518, 0.027

38.832

4.62E-10

38.85

8.19

184.29

LPHN2

TTGAGCATCATCTCCCC

0.12

8.0 : 6.0, 5.0 : 89.0

0.571, 0.053

30.902

2.71E-08

23.73

5.91

95.28

  1. This table summarizes the haplotypes that were found more significantly associated with drug response than the originally identified SNP marker alone. Cell lines categorized as cases here are those which were in the resistant group and those categorized as controls are those in the sensitive group. Figure 2 illustrates the relative position of these SNP markers along the genes. Statistics with NA written indicate that the statistic could not be calculated.